Merck asks the FDA to authorize use of its promising COVID-19 pill
Drugmaker Merck asked U.S. regulators Monday to authorize its pill against COVID-19 in what would be the addition of a new and easy-to-use weapon to the world’s arsenal against the disease.
If cleared by the Food and Drug Administration — a decision that could come in a matter of weeks — it would be the first pill shown to treat COVID-19. All other FDA-backed treatments against the disease require an IV or injection.
An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload in U.S. hospitals and helping to curb outbreaks in poorer countries with weak healthcare systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
The FDA will scrutinize company data on the safety and effectiveness of the drug, molnupiravir, before issuing a decision.
Merck and its partner, Ridgeback Biotherapeutic, said they specifically asked the FDA to grant emergency use for adults with mild to moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.
“The value here is that it’s a pill so you don’t have to deal with the infusion centers and all the factors around that,” said Nicholas Kartsonis, a senior vice president with Merck’s infectious disease unit. “I think it’s a very powerful tool to add to the toolbox.”
Researchers are developing vaccines that could be taken as a capsule, a dissolvable tablet or a nasal spray. But the barriers to success are high.
The company reported this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.
Side effects were similar in patients who got the drug and those in a testing group who received a dummy pill. But Merck has not publicly detailed the types of problems reported, which will be a key part of the FDA’s review.
U.S. officials continue to push vaccinations as the best way to protect against COVID-19. “It’s much, much better to prevent yourself from getting infected than to have to treat an infection,” Dr. Anthony Fauci said while discussing Merck’s drug last week.
But with some 68 million eligible Americans still unwilling to get the shots, effective drugs will be critical to controlling future waves of infection.
Black and Latino residents who aren’t vaccinated have L.A. County’s highest rate of COVID-19. Unvaccinated white people have the highest death rates.
Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens illness by a day or two and blunts the severity of symptoms such as fever, cough and stuffy nose.
Three FDA-authorized antibody drugs have proved highly effective at reducing COVID-19 deaths, but they are expensive, hard to produce and require special equipment and health professionals to deliver.
Assuming that the FDA authorizes the new drug, the U.S. government has agreed to buy enough of the pills to treat 1.7 million people, at a price of roughly $700 for each course of treatment. That’s less than half the price of the antibody drugs purchased by the U.S. government — more than $2,000 per infusion — but still more expensive than many antiviral pills for other conditions.
Merck’s Kartsonis said in an interview that the $700 figure does not represent the final price for the medication.
“We set that price before we had any data, so that’s just one contract,” Kartsonis said. “Obviously, we’re going to be responsible about this and make this drug as accessible to as many people around the world as we can.”
Merck, based in Kenilworth, N.J., has said it is in talks with governments around the world and will use a sliding price scale based on each country’s economic means. Also, the company has signed licensing deals with several Indian generic drugmakers to produce low-cost versions of the drug for lower-income countries.
Several other companies, including Pfizer and Roche, are studying similar drugs and are expected to report results in the coming weeks and months. AstraZeneca is also seeking FDA authorization for a long-acting antibody drug intended to provide months of protection for patients who have immune-system disorders and do not adequately respond to vaccination.
Some experts predict that eventually various COVID-19 therapies will be prescribed in combination to better protect against the worst effects of the coronavirus.
Start your day right
Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week.
You may occasionally receive promotional content from the Los Angeles Times.